1. Executive Summary
1.1 Drug Delivery Technology: Market Review
1.2 Aims, Scope and Format of Report
1.2.1 Chapter Outlines
1.3 Research and Analysis Methods
2. Introduction
2.1 Introduction to Drug Delivery Technologies (DDT)
2.2 Types of Technologies for Drug Delivery
2.2.1 Sustained/Controlled Release Systems
2.2.2 Injection
2.2.3 Needle-Free Injection
2.2.4 Pulmonary, Buccal and Nasal Delivery
2.2.5 Pills and Capsules
2.3 Biopharmaceuticals
2.3.1 Overview of the Biologicals Market
2.3.2 The Biological Drug Industry is Strong
2.4 Biotech Drugs with Associated Drug Delivery Technologies
2.4.1 Pegylated Interferons
2.4.2 Crowded Insulin Market Has Forced Investment in Drug Delivery
2.5 Exubera - Case Study for Alternative Biological Delivery Methods
2.5.1 The First Inhaled Insulin
2.5.2 Description and Development History
2.5.3 Generex and MannKind Developing Next-Generation Oral Insulins
2.5.4 Challenges Facing Afrezza and Oral-lyn
2.6 The Main Challenges for Biological Drug Delivery
3. The World Drug Delivery Technology Market to 2022
3.1 The World Drug Delivery Technology Market: Overview
3.2 Growing Market for Drug Delivery Technology and Services
3.2.1 Revenue Forecast for Overall Drug Delivery Technology Market, 2011-2016
3.2.2 Revenue Forecast for Overall Drug Delivery Technology Market, 2017-2022
3.3 Breakdown of the Global Drug Delivery Technology Market
3.3.1 Revenue Forecast for Oral Drug Delivery Technology, 2011-2016
3.3.2 Revenue Forecast for Oral Drug Delivery Technology, 2017-2022
3.3.3 Revenue Forecast for Inhalation Drug Delivery Technology, 2011-2016
3.3.4 Revenue Forecast for Inhalation Drug Delivery Technology, 2017-2022
3.3.5 Revenue Forecast for Transdermal Drug Delivery Technology, 2011-2016
3.3.6 Revenue Forecast for Transdermal Drug Delivery Technology, 2017-2022
3.3.7 Revenue Forecast for Injectable/Implants Drug Delivery Technology, 2011-2016
3.3.8 Revenue Forecast for Injectable/Implants Drug Delivery Technology, 2017-2022
3.3.9 Revenue Forecast for Ocular Drug Delivery Technology, 2011-2016
3.3.10 Revenue Forecast for Ocular Drug Delivery Technology, 2017-2022
3.3.11 Revenue Forecast for Nasal Drug Delivery Technology, 2011-2016
3.3.12 Revenue Forecast for Nasal Drug Delivery Technology, 2017-2022
3.4 Leading National Markets for Drug Delivery Technology
3.4.1 The US Drug Delivery Technology Market, 2012-2022
3.4.2 The Japanese Drug Delivery Technology Market, 2012-2022
3.4.3 The Leading European Drug Delivery Technology Markets, 2012-2022
3.4.4 Emerging-Economy Drug Delivery Technology Markets
3.4.5 The Chinese Drug Delivery Technology Market, 2012-2022
3.4.6 The Indian Drug Delivery Technology Market, 2012-2022
4. Drug Classes That Can Benefit from Advances in Drug Delivery
4.1 Therapeutic Areas Offering Growth Opportunities
4.1.1 Sales of Biologics Will Stimulate Developments in Drug Delivery
4.1.2 Leading Segments of the Biological Drugs Market in 2011
4.1.3 Monoclonal Antibodies Lead the Biologics Market
4.1.3.1 Prospects for Monoclonal Antibodies and Implications for Drug Delivery
4.1.4 The Human Insulins Class will Exhibit Strong Growth
4.1.5 Erythropoietin Products - What are the Future Prospects?
4.1.5.1 Erythropoietin Products Forecast, 2012-2022
4.1.6 The Interferons Class will Show an Increase in Revenues from 2011-2016
4.1.6.1 Long-Term Forecast for the Interferons Class
4.1.7 Granular-Colony Stimulating Factors (G-CSF) Forecast, 2012-2022
4.1.8 Recombinant Coagulation Factors Will Show Steady Growth
4.1.9 Other Therapeutic Proteins
4.1.10 The Biosimilars Market, 2011
4.1.10.1 Forecast for the Biosimilars Market, 2012-2022
4.1.11 Forecast for the Vaccines Market, 2012-2022
4.2 The Drug Delivery Technology Market: Conclusions
4.2.1 A Rapidly Expanding Segment of the Global Pharma Industry
5. Prominent Companies in the Drug Delivery Technology Market, 2012
5.1 Introduction
5.2 Leading Oral Drug Delivery Companies
5.2.1 Applied Pharma Research (APR)
5.2.1.1 Overview
5.2.1.2 Therapeutic Areas and Technology
5.2.1.3 MonoSol Rx Announced FDA Approval of Zuplenz
5.2.2 Catalent Pharma Solutions
5.2.2.1 Overview
5.2.2.2 Catalent's Oral Drug Delivery Technology
5.2.2.3 Catalent's Customer Base
5.2.2.4 Manufacturing Capabilities
5.2.2.5 Revenues
5.2.2.6 Catalent Pharma Acquires Clinical Trial Supplies Business
5.2.3 Emisphere Technologies
5.2.3.1 Overview
5.2.3.2 Emisphere's Eligen Technology
5.2.3.3 Emisphere's Pipeline Products
5.2.3.4 Emisphere's Partnered Programmes
5.2.3.5 Revenues
5.2.3.6 Future Outlook
5.2.4 Ethypharm
5.2.4.1 Overview
5.2.4.2 Ethypharm's Proprietary Technologies
5.2.4.3 Products on the Market
5.2.4.4 Developmental Pipeline
5.2.5 Aptalis
5.2.5.1 Overview
5.2.5.2 Aptalis' Drug Delivery Platforms
5.2.5.3 Products for Out-Licensing
5.2.5.4 Revenue
5.2.5.5 Future Outlook
5.2.6 Glycologic
5.2.6.1 Overview
5.2.6.2 Glycologic Technology Platform
5.2.6.3 Pipeline Products
5.2.6.4 Future Outlook
5.3 Inhaled Drug Delivery
5.3.1 3M Drug Delivery Systems
5.3.1.1 Overview
5.3.1.2 Protein and Peptide Delivery
5.3.1.3 Excipient Technology for CFC-Free Inhalers
5.3.1.4 Actuator Technology for MDIs
5.3.1.5 Particle Engineering Technology
5.3.1.6 Revenues
5.3.2 Aradigm Corp.
5.3.2.1 Overview
5.3.2.2 AERx Drug Delivery System
5.3.2.3 Collaborations
5.3.2.4 Pipeline Products
5.3.2.5 Revenues
5.3.3 Vectura Group
5.3.3.1 Overview
5.3.3.2 Proprietary Technologies
5.3.3.3 Pipeline Products
5.3.3.4 Revenues
5.4 Injectable Drug Delivery
5.4.1 Alkermes
5.4.1.1Overview
5.4.1.2 Proprietary Technology Platforms
5.4.1.3 Product Pipeline
5.4.1.4 Revenues
5.4.2 Pacira Pharmaceuticals
5.4.2.1 Overview
5.4.2.2 Injectable Sustained-Release Technology
5.4.2.3 Products
5.4.2.4 Pipeline
5.4.2.5 Revenues
5.4.2.6 Future Outlook
5.5 Transdermal Drug Delivery
5.5.1 3M
5.5.1.1 Overview
5.5.1.2 Transdermal Systems
5.5.2 Altea Therapeutics
5.5.2.1 Overview
5.5.2.2 Altea's PassPort Technology Platform
5.5.2.3 Therapeutic Focus
5.5.3 Intercell
5.5.3.1 Overview
5.5.3.2 Vaccine Patch Technology Platform
5.5.3.3 Intercell's Strategic Alliances
5.5.3.4 Revenues
5.5.3.5 Future Outlook
5.5.4 NanoPass Technologies
5.5.4.1 Overview
5.5.4.2 Technology Platform
5.5.4.3 The MicronJet Needle
5.5.4.4 NanoCare
5.5.5 Noven Pharmaceuticals
5.5.5.1 Overview
5.5.5.2 Key Products
5.5.5.3 Transdermal Pipeline
5.5.5.4 Revenues
5.6 Transmucosal Drug Delivery
5.6.1 Overview of Technology
5.6.2 Cima Labs (Cephalon)
5.6.2.1 Overview
5.6.2.2 Cima's Transmucosal Drug Delivery Technologies
5.6.2.3 Products
5.6.3 Columbia Laboratories
5.6.3.1 Overview
5.6.3.2 Bioadhesive Delivery Technology
5.6.3.3 Products
5.6.3.4 Revenue
5.6.3.5 Future Outlook
5.6.4 Generex Biotechnology Corporation
5.6.4.1 Overview
5.6.4.2 Products
5.6.4.3 Pipeline Products
5.6.4.4 Revenue
5.7 Implant Technology
5.7.1 Overview of Technology
5.7.2 pSivida Corp.
5.7.2.1 Overview
5.7.2.2 Technologies and Products
5.7.2.2.1 Durasert Technology System
5.7.2.2.2 BioSilicon Technology System
5.7.2.2.3 CODRUG Technology System
5.7.2.3 Products
5.7.2.4 Revenues
6. Drivers, Restraints and Trends in Drug Delivery
6.1 Analysis of Strengths, Weaknesses, Opportunities and Threats (SWOT)
6.2 Patent Expiry Will Drive Biological Drug Delivery
6.2.1 Biosimilars Legislation Encourages Innovation
6.2.2 As Patents Expire, Competition Will Increase
6.3 Competitive and Lucrative Monoclonal Antibody Market Will Drive Sales
6.4 Biological Drug Delivery Technology is Established
6.4.1 Pegylation Has Imparted Benefits
6.4.2 New Delivery Methods for Insulin?
6.4.3 Nanotechnology Can Benefit Biological Drug Delivery
6.5 Will Regulatory Authorities Hold Back the Market?
6.5.1 Risk-Conscious FDA and EMA Will Make Approval Difficult?
6.5.2 Choice between New Technology or a New Drug? Is a Re-think Needed?
6.6 New Delivery Methods for Biologicals Must be Cost Effective and Appropriate
6.7 Injection is Still the Main Form of Delivery
6.8 Next-Generation Drugs May Limit Drug Delivery Revenues
6.8.1 Lifecycle Management via Protein Engineering Blurs Drug Delivery Lines
6.8.2 New Chemical Entities Could Restrict Biotech Growth
6.9 The Biological Drug Delivery Market Offers Great Potential, But Care is Needed
7. Research Interviews from Our Survey
7.1 Professor Sven Frøkjær, Dean, Faculty of Pharmaceutical Sciences, University of Copenhagen
7.1.1 Market Value for Drug Delivery Systems
7.1.2 Key Benefits for Patients
7.1.3 On Emerging Technologies
7.1.4 On Nanotechnology
7.1.5 On Different Systems
7.1.6 Main Challenges Facing the Sector
7.1.7 On Nanoparticle Systems and Drug Delivery
7.1.8 Systems on the Market
7.1.9 Diseases of Interest
7.1.10 Therapeutic Areas Offering Opportunities
7.2 Dr Bill Lambert, Senior Vice President, Pharmaceutical Development, Pacira Pharmaceuticals
7.2.1 On Pacira and Drug Delivery Technology
7.2.2 Liposomal Drug Delivery
7.2.3 Applications of DepoFoam Technology
7.2.4 On Pacira's Products
7.2.5 Pipeline DDT Platforms
7.2.6 On the Market for Drug Delivery Technology
7.2.7 Therapeutic Areas Offering Opportunities
7.2.8 Challenges Facing the Drug Delivery Industry
7.2.9 Comparing DepoFoam with Other Controlled-Release Systems
7.2.10 Mode of Delivery
7.2.11 Insulin and Liposomal Drug Delivery
7.2.12 R&D and Technologies Likely to Reach Market
7.3 Mr David Harris, Principal Consultant at, Team Consulting Limited
7.3.1 Current Market Value for Drug Delivery Systems
7.3.2 On Key Unmet Needs
7.3.3 On Research Focus in the Next 10-15 Years
7.3.4 On Main Challenges Facing the Sector
7.3.5 On Therapeutic Areas Offering Opportunities
7.3.6 On Pipeline Developments
7.4 Dr Ronan MacLoughlin, Scientist, Aerogen
7.4.1 Current Market Value for Drug Delivery Systems
7.4.2 On Aerogen and its Drug Delivery Systems
7.4.3 On Key Unmet Needs
7.4.4 On Research Focus in the Next 10-15 Years
7.4.5 On Main Challenges Facing the Sector
7.4.6 On Therapeutic Areas Offering Opportunities
7.4.7 On Pipeline Developments
8. Conclusions of Our Research and Analyses
8.1 The Market Shows Potential for Strong Revenue Growth
8.2 Commercial Drivers of Drug Delivery Technology
8.3 Some Prominent Companies in the Market
8.4 Future Outlook and Concluding Remarks
List of Tables
Table 2.1 Top 10 Biotech Drugs, 2010
Table 2.2 Top 10 Biopharma Companies: Revenues, 2008, 2009 and 2010
Table 2.3 Amino Acid Changes for Human Insulin Analogues
Table 3.1 Drug Delivery Technology Market: World Revenues, 2011-2016
Table 3.2 Drug Delivery Technology Market: World Revenues, 2017-2022
Table 3.3 Oral Drug Delivery Technology Market: World Revenues, 2011-2016
Table 3.4 Oral Drug Delivery Technology Market: World Revenues, 2017-2022
Table 3.5 Inhalation Drug Delivery Technology Market: World Revenues, 2011-2016
Table 3.6 Inhalation Drug Delivery Technology Market: World Revenues, 2017-2022
Table 3.7 Transdermal DDT Market: World Revenues, 2011-2016
Table 3.8 Transdermal DDT Market: World Revenues, 2017-2022
Table 3.9 Injectable/Implants DDT Market: World Revenues, 2011-2016
Table 3.10 Injectable/Implants DDT Market: World Revenues, 2017-2022
Table 3.11 Ocular Drug Delivery Technology Market: World Revenues, 2011-2016
Table 3.12 Ocular Drug Delivery Technology Market: World Revenues, 2017-2022
Table 3.13 Nasal Drug Delivery Technology Market: World Revenues, 2011-2016
Table 3.14 Nasal Drug Delivery Technology Market: World Revenues, 2017-2022
Table 3.15 Drug Delivery Technology Submarkets: World Revenues, 2011-2016
Table 3.16 Drug Delivery Technology Submarkets: World Revenues, 2017-2022
Table 3.17 Drug Delivery Technology: Leading National Market Forecasts, 2011-2022
Table 4.1 Leading Drug Classes Driving the Drug Delivery Technology Market, 2010 and 2011
Table 4.2 Some Leading Monoclonal Antibody Drugs, 2012
Table 4.3 Monoclonal Antibodies Market: World Sales Forecast, 2011-2016
Table 4.4 Monoclonal Antibodies Market: World Sales Forecast, 2017-2022
Table 4.5 Insulins Market: World Sales Forecast, 2011-2016
Table 4.6 Insulins Market: World Sales Forecast, 2017-2022
Table 4.7 Erythropoietins Market: World Sales Forecast, 2011-2016
Table 4.8 Erythropoietins Market: World Sales Forecast, 2017-2022
Table 4.9 Some Interferon Drugs, 2012
Table 4.10 Interferons Market: World Sales Forecast, 2011-2016
Table 4.11 Interferons Market: World Sales Forecast, 2017-2022
Table 4.12 G-CSF Market: World Sales Forecast, 2011-2016
Table 4.13 G-CSF Market: World Sales Forecast, 2017-2022
Table 4.14 Some Recombinant Coagulation Factors, 2012
Table 4.15 Recombinant Coagulation Factors Market: World Sales Forecast, 2011-2016
Table 4.16 Recombinant Coagulation Factors Market: World Sales Forecast, 2017-2022
Table 4.17 Some Human Growth Hormones, 2012
Table 4.18 Some Immunosuppressant Products, 2012
Table 4.19 Other Therapeutic Proteins Market: World Sales Forecast, 2011-2016
Table 4.20 Other Therapeutic Proteins Market: World Sales Forecast, 2017-2022
Table 4.21 Some Biosimilar Drugs, 2012
Table 4.22 Biosimilars Market: World Sales Forecast, 2011-2016
Table 4.23 Biosimilars Market: World Sales Forecast, 2017-2022
Table 4.24 Some Vaccines, 2012
Table 4.25 Vaccines Market: World Sales Forecast, 2011-2016
Table 4.26 Vaccines Market: World Sales Forecast, 2017-2022
Table 5.1 Aradigm's Product Pipeline, 2011
Table 5.2 Alkermes' Product Pipeline, 2011
Table 5.3 Intercell's Strategic Alliances, 2012
Table 5.4 Noven's Marketed & Pipeline Transdermal Products, 2012
Table 6.1 SWOT Analysis of the Drug Delivery Industry and Market, 2012
Table 6.2 Some Leading Drugs Expected to Lose Patent Protection, 2012-2015
Table 6.3 Monoclonal Antibody Therapies Approved by the US FDA, 1986-2003
Table 6.4 Monoclonal Antibody Therapies Approved by the US FDA, 2004-2010
Table 6.5 Leading Biologic Drug Types, 2010
Table 8.1 Drug Delivery Technology Market: World Revenues, 2011, 2012, 2016, 2018, 2020 & 2022
List of Figures
Figure 3.1 Drug Delivery Technology Market: World Revenues, 2011-2016
Figure 3.2 Drug Delivery Technology Market: World Revenues, 2017-2022
Figure 3.3 Oral Drug Delivery Technology Market: World Revenues, 2011-2016
Figure 3.4 Oral Drug Delivery Technology Market: World Revenues, 2017-2022
Figure 3.5 Inhalation DDT Market: World Revenues, 2011-2016
Figure 3.6 Inhalation DDT Market: World Revenues, 2017-2022
Figure 3.7 Transdermal DDT Market: World Revenues, 2011-2016
Figure 3.8 Transdermal DDT Market: World Revenues, 2017-2022
Figure 3.9 Injectable/Implants DDT Market: World Revenues, 2011-2016
Figure 3.10 Injectable/Implants DDT Market: World Revenues, 2017-2022
Figure 3.11 Ocular Drug Delivery Technology Market: World Revenues, 2011-2016
Figure 3.12 Ocular Drug Delivery Technology Market: World Revenues, 2017-2022
Figure 3.13 Nasal Drug Delivery Technology Market: World Revenues, 2011-2016
Figure 3.14 Nasal Drug Delivery Technology Market: World Revenues, 2017-2022
Figure 3.15 Drug Delivery Technology Submarkets: World Revenues, 2011-2022
Figure 3.16 US DDT Market: Sales Forecast, 2011-2022
Figure 3.17 Other Leading DDT National Markets: Sales Forecasts, 2011-2022
Figure 3.18 DDT Sales Shares in Leading National Markets, 2011
Figure 3.19 DDT Sales Shares in Leading National Markets, 2015
Figure 3.20 DDT Sales Shares in Leading National Markets, 2019
Figure 3.21 DDT Sales Shares in Leading National Markets, 2022
Figure 4.1 Monoclonal Antibodies Market: World Sales Forecast, 2011-2022
Figure 4.2 Insulins Market: World Sales Forecast, 2011-2022
Figure 4.3 Erythropoietins Market: World Sales Forecast, 2011-2022
Figure 4.4 Interferons Market: World Sales Forecast, 2011-2022
Figure 4.5 G-CSF Market: World Sales Forecast, 2011-2022
Figure 4.6 Recombinant Coagulation Factors Market: World Sales Forecast, 2011-2022
Figure 4.7 Other Therapeutic Proteins Market: World Sales Forecast, 2011-2022
Figure 4.8 Biosimilars Market: World Sales Forecast, 2011-2022
Figure 4.9 Vaccines Market: World Sales Forecast, 2011-2022
Figure 6.1 Different Approaches to Biological Drug Delivery, 2012
Figure 8.1 Drug Delivery Technology Market: World Revenues by Category, 2011, 2012, 2016, 2018, 2020 and 2022
Figure 8.2 Drug Delivery Technology Market: World Revenues, 2011, 2012, 2016, 2018, 2020 and 2022
Figure 8.3 Drug Delivery Technology Market: World Revenue Shares by Category, 2011